<DOC>
	<DOCNO>NCT02011945</DOCNO>
	<brief_summary>The purpose study find dose Nivolumab safely add Dasatinib patient Chronic Myeloid Leukemia .</brief_summary>
	<brief_title>A Phase 1B Study Investigate Safety Preliminary Efficacy Combination Dasatinib Plus Nivolumab Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Confirmed diagnosis Chronic Myeloid Leukemia Chronic Phase Accelerated Phase : With historically document Ph+ cell â‰¥2 prior Tyrosine Kinase Inhibitors ( TKI ) therapy CML Currently progress , resistance suboptimal response recent therapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) Score 0 1 Blast phase CML Known Ablkinase mutation resistant Dasatinib ( e.g . T315I T315A )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>